Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

ClinicalTrials.gov ID: NCT02699450

Public ClinicalTrials.gov record NCT02699450. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. The study will consist of a treatment period (20 weeks) and an observational period (up to 16 weeks). Treatment naive participants will be randomized in a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in a 1:1 ratio to Arms A and C.

Study identification

NCT ID
NCT02699450
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
229 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 27, 2016 (Actual)
Primary completion
Sep 15, 2017 (Actual)
Completion
Dec 14, 2017 (Actual)
Last update posted
Sep 25, 2020

2016 – 2017

United States locations

U.S. sites
60
U.S. states
26
U.S. cities
56
Facility City State ZIP Site status
Retinal Research Institute, LLC Phoenix Arizona 85014 —
Associated Retina Consultants Phoenix Arizona 85020 —
Arizona Retina and Vitreous Consultants Phoenix Arizona 85021 —
Retina Associates Southwest PC Tucson Arizona 85750 —
Retina Consultants of Orange County Fullerton California 92835 —
United Med Res Inst Inglewood California 90301 —
Northern California Retina Vitreous Associates Mountain View California 94040 —
Ophthalmic Clinical Trials San Diego Oceanside California 92056 —
Southern CA Desert Retina Cons Palm Desert California 92211 —
Retina Consultants, San Diego Poway California 92064 —
Retinal Consultants Med Group Sacramento California 95825 —
California Retina Consultants Santa Barbara California 93103 —
Bay Area Retina Associates Walnut Creek California 94598 —
Retina Consultants of Southern Colorado Springs Colorado 80909 —
Rand Eye Deerfield Beach Florida 33064 —
National Ophthalmic Research Institute Fort Myers Florida 33912 —
Florida Eye Associates Melbourne Florida 32901 —
Retina Specialty Institute Pensacola Florida 32503 —
Retina Vitreous Assoc of FL St. Petersburg Florida 33711 —
Southern Vitreoretinal Assoc Tallahassee Florida 32308 —
Southeast Retina Center Augusta Georgia 30909 —
Georgia Retina PC Marietta Georgia 30060 —
Univ of Illinois at Chicago Chicago Illinois 60612 —
University Retina and Macula Associates, PC Oak Forest Illinois 60452 —
Illinois Retina Associates SC Oak Park Illinois 60304 —
Midwest Eye Institute Indianapolis Indiana 46290 —
Wolfe Eye Clinic West Des Moines Iowa 50266 —
Retina Associates of Kentucky Lexington Kentucky 40509 —
Paducah Retinal Center Paducah Kentucky 42001 —
Wilmer Eye Institute Baltimore Maryland 21287 —
Vitreo-Retinal Associates Grand Rapids Michigan 49546 —
Vitreoretinal Surgery Edina Minnesota 55435 —
Sierra Eye Associates Reno Nevada 89502 —
Retina Center of New Jersey Bloomfield New Jersey 07003 —
Eye Associates of New Mexico Albuquerque New Mexico 87102 —
University of New Mexico Albuquerque New Mexico 87131 —
Capital Region Retina Albany New York 12206 —
Opthalmic Consultants of LI Lynbrook New York 11563 —
Retina Consultants of Western New York Orchard Park New York 14127 —
Western Carolina Retinal Associate PA Asheville North Carolina 28803 —
Char Eye Ear &Throat Assoc Charlotte North Carolina 28210 —
Cleveland Clinic Foundation; Cole Eye Institute Cleveland Ohio 44195 —
OSU Eye Physicians & Surgeons Columbus Ohio 43212 —
Oregon Retina, LLP Eugene Oregon 97401 —
Retina Northwest Portland Oregon 97221 —
Palmetto Retina Center Florence South Carolina 29501 —
Charleston Neuroscience Inst Ladson South Carolina 29456 —
Charles Retina Institute Germantown Tennessee 38138 —
Tennessee Retina PC. Nashville Tennessee 37203 —
W Texas Retina Consultants PA Abilene Texas 79606 —
Austin Retina Associates Austin Texas 78705 —
Retina Consultants of Austin Austin Texas 78705 —
Retina Specialists DeSoto Texas 75115 —
Retina Consultants of Houston Houston Texas 77030 —
Med Center Ophthalmology Assoc San Antonio Texas 78240 —
Retina Consultants of Houston The Woodlands Texas 77384 —
Retina Associates of Utah Salt Lake City Utah 84107 —
Univ of Virginia Ophthalmology Charlottesville Virginia 22903 —
Spokane Eye Clinical Research Spokane Washington 99204 —
West Virginia University Eye Institute Morgantown West Virginia 26506 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02699450, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 25, 2020 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02699450 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →